<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687567</url>
  </required_header>
  <id_info>
    <org_study_id>KYXM-201804</org_study_id>
    <nct_id>NCT03687567</nct_id>
  </id_info>
  <brief_title>A Retrospective Study on the Effect of HBA or HBB Genetic Defects on Early Embryonic Development</brief_title>
  <official_title>A Retrospective Study on the Effect of HBA or HBB Genetic Defects on Early Embryonic Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thalassemia is an anemia or pathological state caused by compounding absently or inadequately
      of one or more globin chains of hemoglobin due to the defects of the globin gene,and the
      carrying rate is high in southern China. Although there are many studies of Thalassemia, the
      relationship between the globin gene defects and the early embryo development has not been
      reported.

      This study intends to carry out a retrospective analysis on the embryonic development of the
      patients with thalassemia assisted by PGD from January 1, 2011 to now in our hospital, to
      explore whether the HBA or HBB gene defects have a certain influence on the early embryo
      development, so as to accumulate certain data for reproductive health research.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gardner grading of blastocysts</measure>
    <time_frame>embryo cultured in-vitro for 5-7 days</time_frame>
    <description>development status of blastocysts</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">737</enrollment>
  <condition>Thalassemia,Embryonic Development,Reproductive Sterility and Infertility</condition>
  <arm_group>
    <arm_group_label>HBA</arm_group_label>
    <description>alpha-Thalassemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBB</arm_group_label>
    <description>beta-Thalassemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preimplantation genetic diagnosis</intervention_name>
    <arm_group_label>HBA</arm_group_label>
    <arm_group_label>HBB</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        One or both of infertility couples with thalassemia take PGD treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertility couples with thalassemia(one or both )

          -  infertility couples treat by PGD

        Exclusion Criteria:

          -  abortion of amplification for blastula biopsy

          -  PGD without diagnostic results or with unclear diagnostic results

          -  embryos with both HBA and HBB genetic defect
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Hu, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of CITIC-XIANGYA</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

